Back to search

Finland· FI-REL-REL50716

Agomelatin Sandoz

A agomelatin product containing agomelatine urea, registered in Finland by Sandoz A/S. The same ATC class is registered in 13 of our 19 countries.

ATC N06AX22

Checked against Fimea (Finland) on

Informational only — not a medical device.

SOURCE REGISTER · FIFimea (Finland)normalisedAgomelatin SandozATCN06AX22REGISTER NO.FI-REL-REL50716PACKS LISTED0CHECKEDSeptember 27, 2026

Where it is registered

Agomelatin is registered in 13 of 19 countries.

Countries holding a registration under ATC N06AX22 (agomelatin), each read from that country’s own register.

  • This record: Finland, from Fimea (Finland)
  • 9 of them publish a price we can compare per daily dose

Agomelatin · ATC N06AX22

13 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • Sweden
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of agomelatin costs, country by country.

Normalised to the WHO defined daily dose (25 mg), the median price runs from $0.72 in France to $1.72 in Switzerland — a ×2.4 gap.

  • 2 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Agomelatin · price per daily dose (25 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$1.72
  • FR France$0.72
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Fimea (Finland)
Active substance
Agomelatine urea
Manufacturer
Sandoz A/S
Country
Finland (FI)
ATC code
N06AX22
ATC class
Agomelatin
Defined daily dose
25 mg, O
Reimbursed
Not published by this register
Source register
Fimea (Finland)
Last checked
September 27, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

25 interactions on record for agomelatin.

Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Agomelatin · interactions on record

25 records

25 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
Mechanism and what to do, in the interaction check
Interaction register. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/d5e8ffb3-ec83-4900-816b-cd416abe4ebd
GET /v1/drugs/d5e8ffb3-ec83-4900-816b-cd416abe4ebd?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "ddd": "25",
  "form": "tabletti, kalvopäällysteinen",
  "route": null,
  "ddd_unit": "mg",
  "strength": "25 mg",
  "atc_label": "agomelatiini",
  "ma_number": "35030",
  "auth_status": "Myyntilupa peruuntunut",
  "eu_ma_number": null,
  "fimea_rel_id": "REL50716",
  "authorised_at": "2018-06-29"
}

See everything about agomelatin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.